EAU 2022 | Ongoing studies assessing oncolytic virotherapy in urological malignancies

Geertje Van Der Horst, PhD, Leiden University Medical Centre, Leiden, The Netherlands, discusses clinical trials assessing oncolytic viruses as therapies for patients with genitourinary cancers, an emerging technology in oncology. The majority of studies are in early phase however talimogene laherparepvec (T-VEC) has gained approval in other solid tumors. Adenoviruses are under investigation for patients with prostate cancer and have been designed to target PSMA-producing cells. This interview took place at the European Association of Urology (EAU) Meeting 2022.